Download Files:

Asenapine (citrate)

Products Details

Product Description

– Asenapine citrate, an atypical antipsychotic, is an antagonist of serotonin receptors (pKi: 8.4-10.5), adrenoceptors (pKi: 8.9-9.5), dopamine receptors (pKi: 8.9-9.4) and histamine receptors (pKi: 8.2-9.0). Asenapine citrate can be used in the research of schizophrenia and bipolar disorder[1][2].

Web ID

– HY-10121B

Shipping

– Room temperature

Applications

– Neuroscience-Neuromodulation

Molecular Formula

– C23H24ClNO8

References

Р[1]M Shahid, et al. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73.|[2]Olivia Fr̴nberg, et al. Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology (Berl). 2008 Feb;196(3):417-29.

CAS Number

– 1411867-74-7

Molecular Weight

– 477.89

SMILES

– ClC1=CC=C2OC3=CC=CC=C3[C@@](C4)([H])[C@](CN4C)([H])C2=C1.O=C(CC(C(O)=O)(O)CC(O)=O)O

Clinical Information

– Launched

Research Area

– Neurological Disease

Solubility

– 10 mM in DMSO

Target

– 5-HT Receptor;Adrenergic Receptor;Dopamine Receptor;Histamine Receptor

Isoform

– 5-HT1 Receptor;5-HT2 Receptor;5-HT5 Receptor;5-HT6 Receptor;5-HT7 Receptor;D1 Receptor;D2 Receptor;D3 Receptor;D4 Receptor;H1 Receptor;H2 Receptor;α adrenergic receptor

Pathway

– GPCR/G Protein;Immunology/Inflammation;Neuronal Signaling

Product type

– Reference compound

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.